Skip to content
Skip to content
Healthcare

The regulator called your funnel a health record

Nearly a quarter of Dutch women track a cycle in an app. On 4 August their regulator said out loud what the industry had been mumbling: nobody can see where that data goes.

Summarise with
Set as preferred source on Google
19 min read
Quick answerdigital health marketing now carries special category risk. The Dutch regulator warned on 4 August that intimate cycle-app data can reach advertisers unintentionally, and said it may open an investigation into those apps.
Section 01

Lesson one: the event is the diagnosis

digital health marketing

On 4 August the Dutch Data Protection Authority put period apps on notice, and anyone practising digital health marketing should read that warning as a mirror rather than someone else's misfortune. The Autoriteit Persoonsgegevens, the AP, said sensitive information can reach advertisers unintentionally, and it named the data without flinching: when you had sex, whether you are pregnant, whether you have had a miscarriage, as reported by Emerce. Nearly one quarter of Dutch women use such an app.

That is the first brutal lesson of digital health marketing, and it is the one that decides the other four: the event is the diagnosis. A conversion called pregnancy_confirmed is not a marketing signal wearing a lab coat. It is data concerning health and, where it touches intimacy, data concerning a person's sex life. Both sit inside the special categories set out in Article 9 GDPR, where processing is prohibited by default and permitted only through narrow exceptions. The pixel does not care. The regulator does.

Dutch women using a cycle or fertility app
Donut chart illustrating that close to one in four Dutch women use a cycle or fertility app.Use a cycle or fertility app: 25%Do not use one: 75%~1 in 4
Use a cycle or fertility app 25%Do not use one 75%
Illustrative, not a measurement: the AP reported, via Emerce, that nearly one quarter of Dutch women use such an app, and this split is drawn to that description rather than to a published decimal.

Marketers protest that they never sent a diagnosis, only a page view. Follow the trail the way a fox follows a hedgerow and the protest collapses. A URL such as /fertility/ivf-costs/ carries the condition in the string. A remarketing audience named "cycle app, trying to conceive" carries the condition in the label. An offline conversion upload carries it in the join key.

Health data privacy is not a field you tick at the end. It is a property of the whole path, and the path is precisely what the pixel copies. Digital health marketing lives along that path, which is why a serious audit starts with URLs, audience names and event parameters rather than with policy documents nobody reads.

AP Vice President Monique Verdier put the exchange in one line, as reported by Emerce: with free apps you often pay with your data. She added, per the same report, that the AP has these apps in its sights and does not rule out starting an investigation, which is regulator language for a torch already lit at the mouth of the burrow. The three duties are set out in the authority's own Autoriteit Persoonsgegevens notice, and the warning was also reported by the Dutch healthcare title Skipr.

With free apps you often pay with your data.
Monique Verdier, Vice President, Autoriteit Persoonsgegevens, quoted by Emerce

Those duties read like product requirements because that is what they are. Prove a lawful basis before you collect or share, tell people plainly and beforehand what happens next, and lock the doors. For teams building healthcare marketing programmes, that trio is the whole brief: legality, legibility, locks. Every remaining lesson below is a variation on those three, and every failure below began when a digital health marketing team assumed someone else owned them. Mature digital health marketing treats the three duties as build tickets with owners and dates, not as a policy page collecting no scrutiny until an investigator arrives.

Section 03

Lesson three: the landing page writes the ad

On 29 July the Advertising Standards Authority upheld a complaint about two Facebook ads from Bolt Healthcare Ltd, trading as Bolt Pharmacy. One ad ran an "Affordable Weight Loss" pricing alert. The other leaned on a "system crashed pricing error" angle. Neither named a medicine. Both were still held to promote prescription-only medicines to the public, because the landing pages reached through them displayed Wegovy and Mounjaro, per the Advertising Standards Authority ruling.

Rule 12.12 of the CAP Code was breached and the ads must not appear again. Read that mechanism twice, because it is the one that catches careful teams. The copy was clean, the destination was not, and the ASA treated the journey as a single continuous message. Your funnel is not a stack of separate documents. It is one trail, and the regulator follows it the way a fox follows a hedgerow at dusk, snout down, patient, all the way to the end of the path.

Copy reviewed on its own

Legal signs off the ad text, the landing page belongs to a different team on a different sprint, and nobody re-reads the pair after launch.

Ad and destination reviewed as one message

One artefact holds the creative, the destination URL, a dated screenshot of that destination and the reviewer's name, so the journey is defensible months later.

What the ASA ruling changes for digital health marketing

Three habits follow. First, review creative and landing page together, in the same session, with the same reviewer. Second, freeze the destination, because if a page can be edited by another team after approval then your approval was worthless. Third, log the pairing with a timestamp, since the defence you will need is evidence that the page shown on the day matched the page signed off. Disciplined content marketing and healthcare marketing compliance are the same discipline wearing different hats.

The weight-loss category makes this vivid because urgency sells, and urgency is exactly what the codes distrust. A pricing error framing manufactures scarcity around a prescription decision. Strip the scarcity and keep the clarity, and the campaign still complies. The ASA's objection was to the promotion, not to the proposition. The quiet quarry comes closer when you stop crashing through the bracken after it. Restraint reads like a creative constraint in this category right up until you price the alternative, which in the Bolt case was a published ruling, a named advertiser and two adverts that must never run in that form again.

For digital health marketing teams buying across paid social and search, the operational fix is dull and dependable. One approval artefact per advert, containing creative, destination, screenshot and reviewer. Dull beats defending a ruling, and a ruling stays published long after the campaign budget has been spent.

Section 04

Lesson four: private and secure is a representation

On 29 July the Federal Trade Commission, joined by the State of Utah and the Los Angeles County Counsel for California, acted against Hims & Hers in the US District Court for the Northern District of California. The complaint alleges the company shared consumer health information relating to conditions such as erectile dysfunction and hair loss with Meta and Snap, through customer lists and tracking technologies, while marketing itself as "100% online, private and secure", as reported by Forbes.

The billing allegations bite just as badly. The complaint alleges that a "Pay $0 today" claim was followed by immediate charges once a prescription was written. One consumer, the FTC alleges, was charged $897 before speaking to a healthcare professional. Another is alleged to have been charged $147 for Lexapro after saying only that they were "open to" medication. Refills, the complaint alleges, were billed ten days earlier than customers expected. Counts are pleaded under FTC Act section 5 and ROSCA, plus Utah's Consumer Sales Practices Act and California's False Advertising and Unfair Competition laws, per Frier Levitt.

Two charges named in the complaint, in US dollars
Two charges named in the complaint, in US dollarsBar chart comparing an $897 charge made before the consumer spoke to a healthcare professional with a $147 charge for Lexapro.Charged before speaking to a healthcare professional: 897Charged for Lexapro after saying only "open to" medication: 147897672.8448.5224.20Charged beforeCharged for Le
Two individual charges pleaded in the case, reported by Frier Levitt: a subscription promise of nothing today became, the complaint alleges, hundreds of dollars before a clinician was ever reached.

Hims & Hers called the charges baseless. Its stock fell over 11% regardless, which is simply the market pricing the cost of a discovery process. The underlying Federal Trade Commission release sets out the states' involvement. Whatever the eventual outcome, the lesson for digital health marketing is already banked: the promise in your hero section is a representation, and your tag manager either honours it or contradicts it in public.

That is why pixel governance belongs in the digital health marketing plan and not in a quarterly IT ticket. We set out the specifics in our piece on tracking pixels and the FTC, and the pattern has not shifted since: a tag deployed for a legitimate purpose gathers a condition it was never scoped to touch, then a customer list built for lookalikes ferries that condition to a platform. Nobody chose it. Everybody signed it off.

Give digital health marketing formal ownership of the container, with a named owner, a quarterly review and the authority to delete a tag on the spot, and the scent goes cold before a regulator ever picks it up.

The correct posture is adversarial towards your own stack. Assume a regulator will map every hop the data takes, because inside a single week, regulators in the Netherlands, the United States and the United Kingdom each did exactly that. Health data privacy failures rarely start with malice. They start with convenience: an SDK left on defaults, a list exported for one campaign and never deleted, a helpful developer adding a parameter because reporting asked for richer detail.

Section 05

Lesson five: draw the line before the regulator does

From 2 August 2026 the EU AI Act's transparency obligations apply, and users must be clearly informed when they are not interacting with a real person but an AI system, per the European Commission. Penalties reach 15 million euro or 3% of global annual turnover for companies. The Act entered into force on 1 August 2024, so nobody can plead surprise. If your intake flow uses a chat assistant to triage symptoms, that disclosure is now a compliance surface, and digital health marketing owns it because marketing built the widget.

What non-compliance is worth, to scale
EU AI Act maximum corporate penalty
15m euro or 3% of turnover
Fine referenced by noyb in the Condé Nast matter
750,000 euro
Illustrative, not a measurement: bars are scaled to the two published figures, the 15 million euro AI Act ceiling from the European Commission and the 750,000 euro fine cited by noyb, and the two are different kinds of number (a statutory maximum and a single issued fine).

So where does the line sit between useful measurement and special category exposure? Draw it at the moment a signal identifies both a person and a condition. Measure volume, never the individual. Count that a booking happened, not what it was for. Keep condition-level detail inside first-party systems under a written lawful basis, and send platforms only coarse, aggregated confirmation. That is not a concession, it is a competitive edge: the teams still standing after the next enforcement wave will be the ones with clean, consented data.

The workable line, in four moves
Inventory

List every tag, SDK and export that fires on a health page or in an app session.

Classify

Mark each signal against Article 9: does it reveal a condition, a treatment or a sex life?

Coarsen

Replace condition-level events with neutral, aggregated confirmations before anything leaves your estate.

Evidence

Record the lawful basis, the consent wording and the approval date, so the file answers before you do.

First-party data looks like the obvious refuge, but it decays, which is the argument we made in our piece on first-party audience decay. The answer is not to hoard harder. It is to earn re-permission through content people genuinely want: editorial rather than extraction. A guide worth reading builds a den people return to, while a scraped list rots in a spreadsheet, and no amount of clever brand strategy revives an audience that never agreed to be there.

Consent-led digital health marketing is slower to build and far harder for a competitor to copy, because permission cannot be bought in a bulk upload.

There is an upside worth naming, and it is not consolation. Our own view, set out in how EU telehealth providers win AI citations, is that explicit, well-sourced, structurally clear pages are the easiest for an answer engine to quote, and that the same rigour drives SEO and GEO results. Compliant digital health marketing and citable digital health marketing turn out to be the same craft, practised with a straight face.

One ruling, two enforcement filings, a regulator's warning and a new transparency deadline, all inside a single week. The pattern is not a crackdown, it is a correction: health signals were always special category data, and the tooling simply outran the paperwork. Fix the paperwork, prune the tags, and prowl the perimeter of your own stack before an investigator tracks it for you. Vulpine patience beats panic here, and the teams who move first will own the trust everyone else spends the next year rebuilding. If you want a second pair of eyes on the trail your funnel leaves behind, talk to us, and bring your tag manager.

Questions

Frequently asked questions

Is a page view on a health website really health data?

It can be. If the URL, the audience name or the event parameter reveals a condition alongside an identifier, you are processing data concerning health, which Article 9 GDPR treats as a special category. The Dutch DPA made the same point about cycle apps: the sensitivity sits in what the signal reveals, not in what you intended to collect. Test each signal by asking whether a person and a condition become knowable together.

Can I still run retargeting for a healthcare brand?

Yes. Digital health marketing survives retargeting perfectly well, provided the audience never encodes a condition. Retarget from neutral surfaces such as the homepage, a careers page or a general blog, and stop retargeting from condition-specific pages, symptom checkers and post-consultation confirmations. Keep condition-level detail in first-party systems under a written lawful basis and send platforms only coarse confirmations. The rule of thumb: if the audience name would embarrass a patient, the audience should not exist.

What did the Dutch regulator actually say about period apps?

On 4 August 2026 the Autoriteit Persoonsgegevens warned that menstruation and fertility apps handle extraordinarily intimate data, including when someone had sex, whether they are pregnant and whether they have had a miscarriage, and that it can reach advertisers unintentionally. Vice President Monique Verdier noted that with free apps you often pay with your data, and said the AP has these apps in its sights and does not rule out an investigation.

The BBC's investigation names the Stardust app and quotes EPIC's Sara Geoghegan on where that data actually goes.

Does an advertising ruling apply if my ad never names a medicine?

It can. In the Bolt Pharmacy case the ASA upheld a complaint about two Facebook ads whose copy named no medicine, because the landing pages reached through those ads displayed Wegovy and Mounjaro. The ASA treated the ad and its destination as one message and found a breach of CAP Code rule 12.12. Review creative and landing page together, and freeze the destination after approval.

What does the EU AI Act require from a chat assistant on my site?

From 2 August 2026, transparency obligations apply and users must be clearly informed when they are not interacting with a real person but an AI system. Penalties reach 15 million euro or 3% of global annual turnover for companies. In practice, label the assistant at the first message, keep the label visible, and make the handover to a human obvious rather than hidden behind a menu.

How many advertising partners is too many in a consent banner?

Any number a person cannot reasonably review. noyb argues that 1,741 partners bundled into one click cannot produce consent that is freely given, informed, specific and unambiguous, since reading those policies at six minutes each would take 170 hours. For health services, keep the vendor list short enough to print on one page, name each recipient, and let people accept them in meaningful groups.

Keep reading

Read more on this topic

Marketing a health product without inheriting the liability?

folkfox builds acquisition for healthcare and telehealth brands where consent, creative and the destination page all tell the same story.

The den

Where to?

Pricing

Choose a section. Enter opens it, Escape continues reading.

Cookie preferences

folkfox uses data the way we use strategy: only when it earns its place.